Vamsi Labs DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Incyte's Phase 3 frontMIND Tafasitamab Trial Hits PFS Goal

13 Jun 2026

// BUSINESSWIRE

CDSCO Approves Enhertu for First-line HER2-Positive Breast Cancer

13 Jun 2026

// EXPRESSPHARMA

Chiesi Group Complete Acquisition KalVista Pharma for $1.9B

13 Jun 2026

// CONTRACTPHARMA

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

CPhI China

Exhibiting

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

9 Corporate Content #SupplierSpotlight, 2 Data Compilation #PharmaFlow

media
9 Corporate Content #SupplierSpotlight
2 Data Compilation #PharmaFlow

ACTIVE PHARMA INGREDIENTS

43 All APIs, 16 USDMF, 12 CEP/COS, 12 EU WC, 3 KDMF, 6 NDC API, 38 Listed APIs

43 All APIs
16 USDMF
12 CEP/COS
12 EU WC
3 KDMF
6 NDC API
38 Listed APIs

INTERMEDIATES

31 All Intermediates

31 All Intermediates

KEY PRODUCTS

Budesonide, Clenbuterol Hydrochloride, Fenoterol Hydrobromide, Fluticasone Furoate, Fluticasone Propionate, Formoterol Fumarate, Glycopyrronium Bromide, Glycopyrronium Tosylate, Haloperidol, Haloperidol Decanoate, Haloperidol Lactate, Indacaterol Maleate, Ipratropium Bromide, Salmeterol Xinafoate, Tiotropium Bromide, Triamcinolone, Triamcinolone Acetonide, Vilanterol Trifenatate

Budesonide
Clenbuterol Hydrochloride
Fenoterol Hydrobromide
Fluticasone Furoate
Fluticasone Propionate
Formoterol Fumarate
Glycopyrronium Bromide
Glycopyrronium Tosylate
Haloperidol
Haloperidol Decanoate
Haloperidol Lactate
Indacaterol Maleate
Ipratropium Bromide
Salmeterol Xinafoate
Tiotropium Bromide
Triamcinolone
Triamcinolone Acetonide
Vilanterol Trifenatate

INSPECTIONS & REGISTRATIONS

2 FDA, 1 EDQM, 1 WHO-GMP, 2 Third-Party Audit

inspections
2 FDA
1 EDQM
1 WHO-GMP
2 Third-Party Audit

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

About

Vamsi Labs, established in 1991, is a leading Indian API manufacturer specializing in anti-asthmatic, anti-migraine, and anti-psychotic APIs for domestic and international markets (50% sales). Anti-asthma products account for 60% of sales. Vamsi maintains high standards in corporate governance, transparency, professionalism, and environmental protection. It is USFDA, EDQM, ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 certified, with a DSIR-certified R&D lab, supporting continuous innovation and global growth. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

CPhI ChinaCPhI China

Industry Trade Show

Exhibiting

16-18 June, 2026

Shanghai, China
CPhI South East AsiaCPhI South East Asia

Industry Trade Show

Exhibiting

08-10 July, 2026

Bangkok, Thailand
CPhI MilanCPhI Milan

Industry Trade Show

Booth #2F114

06-08 October, 2026

Milan, Italy

CONTACT DETAILS

Click the arrow to open the dropdown

Country

India

Address

A-14, A-15, A-31, A-32 & A-33, MIDC Area, Chincholi, Solapur - 413255, Maharas...

Telephone

+91 2172357274

marketing@vamsilabs.com

Website

https://www.vamsilabs.com/

https://in.linkedin.com/company/vamsi-labs-ltd

YouTube

Digital content

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

Product List 2023

Open PDF

Upload

Corporate Presentation

GMP Certificate 2024

API Product List 2023

Open PDF

Upload

Intermediates Product List 2023

Open PDF

Upload

APIs Under Development 2023

USFDA EIR Letter

GMP Certificate 2022-2023

WHO GMP 2021-2024

DATA COMPILATION #PharmaFlow

DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications: Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program: Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry.

Impressions: 4786

DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024. Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each. The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders). View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453 US$ 3,21,920 Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427 US$ 2,31,952 FDF—Foreign US$ 2,35,427 US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629 US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852 US$ 7,56,666 Small business generic drug applicant US$ 1,72,963 US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.

Impressions: 10755

ALL APIs

Click the button for full data set

01

Haloperidol

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

USDMF

Click Us!

CEP/COS

JDMF EU-WC

NDC

KDMF VMF Others AUDIT

02

Tiotropium Bromide

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

USDMF

CEP/COS

JDMF EU-WC

NDC KDMF VMF Others AUDIT

03

Fenoterol Hydrobromide

India

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

USDMF

CEP/COS

JDMF EU-WC

NDC

KDMF

VMF Others AUDIT

09

Salmeterol Xinafoate

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

USDMF

CEP/COS

JDMF EU-WC

NDC KDMF VMF Others AUDIT

10

Budesonide

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

USDMF CEP/COS

JDMF EU-WC

NDC KDMF

VMF Others AUDIT

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

Albuterol Sulfate Usp

India

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

Rev. Date :

Pay. Date :

DMF Number : 42593

Submission : 2025-11-22

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

02

Clenbuterol Hydrochloride Ep

India

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

Rev. Date :

Pay. Date :

DMF Number : 40283

Submission : 2024-08-06

Status : Inactive

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

03

Cyproheptadine Hydrochloride- Ep

India

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

Rev. Date :

Pay. Date :

DMF Number : 40578

Submission : 2024-09-30

Status : Inactive

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

04

Fenoterol Hydrobromide-ep

India

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

Rev. Date :

Pay. Date :

DMF Number : 40580

Submission : 2024-09-26

Status : Inactive

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

05

Fluticasone Furoate Ep

India

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

Rev. Date :

Pay. Date :

DMF Number : 40418

Submission : 2024-08-26

Status : Inactive

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

06

Fluticasone Propionate Ep

India

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

Rev. Date :

Pay. Date :

DMF Number : 40285

Submission : 2024-08-13

Status : Inactive

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

07

Fluticasone Propionate Usp

India

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

Rev. Date :

Pay. Date :

DMF Number : 42812

Submission : 2025-11-25

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

08

Formoterol Fumarate Dihydrate Ep

India

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

Rev. Date :

Pay. Date :

DMF Number : 40450

Submission : 2024-08-31

Status : Inactive

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

09

Formoterol Fumarate Dihydrate Usp

India

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

Rev. Date :

Pay. Date :

DMF Number : 42810

Submission : 2025-11-01

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

10

Haloperidol Usp

India

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

Rev. Date :

Pay. Date :

DMF Number : 34283

Submission : 2019-11-14

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Only 10 entries up to this point, click to access all

LISTED APIs

01

Azelastine Hydrochloride

India

India

CPhI China

India

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

CAS Number : 1209437-82-0

End Use API : Ipratropium Bromide

Intermediate Web Link

Market Place

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KEY PRODUCTS

TOP RANKED SUPPLIER FOR:

Inspections and registrations

Check the inspections & registration from this company

FDA

01 FDA Audited

USA

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

District Decision : Voluntary Action Indicated

Inspection End Date : 2018-03-16

Vamsi Labs

City : Solapur North

State :

Country/Area : India

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2018-03-16

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02 FDA Audited

USA

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

District Decision : Voluntary Action Indicated

Inspection End Date : 2018-03-16

Vamsi Labs

City : Solapur North

State :

Country/Area : India

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2018-03-16

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EDQM

01

GMP Certified

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

Type : GMP Certificates

Number : ES/079/24

EudraGMDP Key : 170787

Country : India

Issue Date : 2024-06-27

Post Code : 413255

NCA Ref : 12342-001

City : Solapur

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

WHO-GMP

01 WHO GMP Certified

Switzerland

CPhI China

Exhibiting

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Vamsi Labs

Name and address of WHO GMP certified Manufacturer : A-14/15, MIDC AREA, CHINCHOLI, SOLAPUR 413255

Country : India

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

THIRD-PARTY AUDIT

Eurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

01 Eurofins Assurance

Belgium

Get Site Audit

CPhI Milan

Exhibiting

Eurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

Vamsi

Country : India

City/Region : Solapur

Audit Date : 2025-09-08

Audit Type : On-Site

02 Eurofins Assurance

Belgium

Get Site Audit

CPhI Milan

Exhibiting

Eurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

Vamsi

Country : India

City/Region : Solapur

Audit Date : 2024-12-03

Audit Type : On-Site

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Contact Vamsi Labs and get a quotation

Vamsi Labs is a supplier offers 43 products (APIs, Excipients or Intermediates).

Find Haloperidol bulk with DMF, CEP, WC offered by Vamsi Labs

Find Tiotropium Bromide bulk with DMF, CEP, WC offered by Vamsi Labs

Find Fenoterol Hydrobromide bulk with CEP, WC offered by Vamsi Labs

Find Fluticasone Furoate bulk with CEP, WC offered by Vamsi Labs

Find Fluticasone Propionate bulk with CEP, WC offered by Vamsi Labs

Find Formoterol Fumarate bulk with CEP, WC offered by Vamsi Labs

Find Ipratropium Bromide bulk with CEP, WC offered by Vamsi Labs

Find Salbutamol Sulphate bulk with CEP, WC offered by Vamsi Labs

Find Salmeterol Xinafoate bulk with CEP, WC offered by Vamsi Labs

Find Budesonide bulk with CEP, WC offered by Vamsi Labs

Find Clenbuterol Hydrochloride bulk with CEP offered by Vamsi Labs

Find Cyproheptadine Hydrochloride bulk with WC offered by Vamsi Labs

Find Fluticasone Propionate bulk with DMF offered by Vamsi Labs

Find Formoterol Fumarate bulk with DMF offered by Vamsi Labs

Find Haloperidol Decanoate bulk with WC offered by Vamsi Labs

Find Loperamide Hydrochloride bulk with DMF offered by Vamsi Labs

Find Salbutamol Sulphate bulk with DMF offered by Vamsi Labs

Find TRIAMCINOLONE ACETONIDE USP bulk with DMF offered by Vamsi Labs

Find Glycopyrronium bromide, Micronised bulk with CEP offered by Vamsi Labs

Find Azelastine Hydrochloride bulk offered by Vamsi Labs

Find Beclomethasone Dipropionate bulk offered by Vamsi Labs

Find Ciclesonide bulk offered by Vamsi Labs

Find Clobetasol Propionate bulk offered by Vamsi Labs

Find Dexamethasone bulk offered by Vamsi Labs

Find Dexamethasone Sodium Phosphate bulk offered by Vamsi Labs

Find Entecavir Monohydrate bulk offered by Vamsi Labs

Find Glycopyrronium Bromide bulk offered by Vamsi Labs

Find Glycopyrronium Tosylate bulk offered by Vamsi Labs

Find Haloperidol Lactate bulk offered by Vamsi Labs

Find Indacaterol Acetate bulk offered by Vamsi Labs

Find Indacaterol Maleate bulk offered by Vamsi Labs

Find Levalbuterol Hydrochloride bulk offered by Vamsi Labs

Find Levalbuterol Sulfate bulk offered by Vamsi Labs

Find Levalbuterol Tartrate bulk offered by Vamsi Labs

Find Mometasone Furoate bulk offered by Vamsi Labs

Find Prednisolone Acetate bulk offered by Vamsi Labs

Find Procaterol bulk offered by Vamsi Labs

Find Sumatriptan bulk offered by Vamsi Labs

Find Triamcinolone bulk offered by Vamsi Labs

Find Triamcinolone Acetonide bulk offered by Vamsi Labs

Find Tulobuterol Hydrochloride bulk offered by Vamsi Labs

Find Vilanterol Trifenatate bulk offered by Vamsi Labs

Find Zoledronic Acid bulk offered by Vamsi Labs

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Company profile for Vamsi Labs

VIRTUAL BOOTH

CONTACT DETAILS

Google Map, LinkedIn, Emails...

EVENTS

Webinars & Exhibitions

DIGITAL CONTENT

9 Corporate Content #SupplierSpotlight

2 Data Compilation #PharmaFlow

ACTIVE PHARMA INGREDIENTS

43 All APIs

16 USDMF

12 CEP/COS

12 EU WC

3 KDMF

6 NDC API

38 Listed APIs

INTERMEDIATES

31 All Intermediates

KEY PRODUCTS

INSPECTIONS & REGISTRATIONS

2 FDA

1 EDQM

1 WHO-GMP

2 Third-Party Audit

01

02

03

04

05

06

07

08

09

10

01

02

03

04

05

06

07

08

09

10

01

02

03

04

05

06

07

08

09

10

27475-14-5

Vamsi Labs, established in 1991, is a leading Indian API manufacturer specializing in anti-asthmatic...

01

97664-55-6

Vamsi Labs, established in 1991, is a leading Indian API manufacturer specializing in anti-asthmatic...

02

943969-38-8

Vamsi Labs, established in 1991, is a leading Indian API manufacturer specializing in anti-asthmatic...

03

43229-01-2

Vamsi Labs, established in 1991, is a leading Indian API manufacturer specializing in anti-asthmatic...

04